SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

CTech’s Book Review: What strategy really is and why so many organizations get it wrong

British Ambassador to Israel, Simon Walters: “If you build in Britain, we will back you”

The end-of-year tech layoffs are not a crisis - they mark a paradigm shift

MSC denies interest in acquiring ZIM

Buzz

Most popular

Daily

Weekly

1

Huang declares Israel Nvidia’s “second home” with record-breaking campus investment

2

Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation

3

Cyera raises $400 million at $9 billion valuation in Blackstone-led round

4

Dell acquires AI data-infrastructure startup Dataloop in $120 million all-cash deal

5

“The acquisition of Armis marks a clear entry by ServiceNow into cybersecurity”

Sanofi

6 stories about Sanofi

CTech The growth conference Katie Kushnir Ventura

“People learn, people develop”: Sanofi Israel’s HR Head sees “only positives” in AI

10.06.25|Amy Shapiro

Speaking with CTech at the Israel Growth Conference, Sanofi Israel’s Katie Kushnir Ventura shared how the pharmaceutical giant is using AI to improve its operations and support employees through upskilling and easier access to digital resources.

מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman

Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.

ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman

Duvakitug signals a brighter future for the Israeli pharma giant.

מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman

Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.

Nucleai raises $33 million for spatial biology drug development platform

22.03.22|Meir Orbach

The technology developed at the Israeli startup allows better prediction of the patient's response to specific oncological treatment, saves on the ongoing process of testing different drugs and improves the chances of the development of new cancer drugs

עומרי שור מנכ"ל מדיסייף

Medisafe raises $30 million in Series C led by pharma giant Sanofi

25.02.21|Meir Orbach

The company expanded its platform in 2020 with the launch of Medisafe Care Connector, which digitally connects patients and doctors